Chondroitin effective for osteoarthritis

Chondroitin effective for osteoarthritis

Brian McAvoy
PEARLS No.
482
Clinical question

How effective is chondroitin for treating osteoarthritis (OA) compared to placebo, active controls or herbal medications?

Bottom line

Chondroitin (alone or in combination with glucosamine) was better than placebo in improving pain in participants with OA in short-term studies (< six months). The benefit was small to moderate, with an eight point greater improvement in pain (range 0 to 100; NNT* 5) and a two point greater improvement in Lequesne Index, a combination of pain, physical function and disability (range 0 to 24), both seeming clinically meaningful. Chondroitin had a lower risk of serious adverse events compared with control. There was also a statistically significant lesser reduction in minimal joint space width with chondroitin compared to placebo, based on moderate to high quality evidence.
*NNT = number needed to treat to benefit one individual.

Caveat

The majority were studies of knee OA (a few hand, one hip) ranging from one month to three years. Several studies were funded by makers of chondroitin.

Context

OA is common, and is one of the leading causes of disability. Chondroitin has emerged as a new treatment, and is popular among patients as an over-the-counter supplement.

Cochrane Systematic Review

Singh JA et al. Chondroitin for osteoarthritis. Cochrane Reviews, 2015, Issue 3. Art. No.: CD005614.DOI: 10.1002/14651858. CD005614.pub2. This review contains 43 studies involving 9,110 participants.

 

Cochrane Systematic Reviews for primary care practitioners
Developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the Ministry of Health and New Zealand Doctor. PEARLS are meant for educational use and not to guide clinical care. New Zealanders can access the Cochrane Library free via www.cochrane.org.nz